CRT 2026

Cardiotube Interview: LBCT: Two-year Outcomes From A Large-scale, Randomized Trial Of Lesion Preparation With Orbital Atherectomy Vs. Balloon Angioplasty In Severely Calcified Coronary Arteries: The Eclipse Trial

Interviewer(s)

• 

  C. Michael Gibson, MD

  Professor of Medicine
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure information not submitted.

Interviewee(s)

• 

  Gregg W. Stone, MD, FACC, MSCAI

  Physician
  Mount Sinai
  New York, New York, United States

  Disclosure(s): Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)